Valganciclovir Dosing in Kidney Transplant Recipients for the Prevention of Cytomegalovirus (CMV) Viremia
نویسندگان
چکیده
منابع مشابه
Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients
OBJECTIVES Cytomegalovirus (CMV) infections in liver transplant recipients are common and result in significant morbidity and mortality. Intravenous ganciclovir or oral valganciclovir are the standard treatment for CMV infection. The present study investigates the efficacy of oral valganciclovir in CMV infection as a preemptive treatment after liver transplantation. METHODS Between 2012 and 2...
متن کاملValganciclovir: Dosing Strategies for Effective Cytomegalovirus Prevention
Valganciclovir has widely become the agent of choice for the prevention of cytomegalovirus in recipients of organ transplants. Optimal dosing is needed to achieve efficacy and avoid toxicity. For subjects at high risk of cytomegalovirus, it is strongly suggested that full-dose (based on renal function) valganciclovir be used. While low-dose valganciclovir appears to be efficacious in some repor...
متن کاملSuccessful Cost-Effective Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients Using Low-Dose Valganciclovir.
OBJECTIVES Low-dose valganciclovir prophylaxis is still under investigation in renal transplant procedures. Our aim was to assess the cost effectiveness of 450 mg versus 900 mg valganciclovir prophylaxis in kidney transplant recipients. MATERIALS AND METHODS In this prospective trial, 201 kidney transplant patients were randomized (1:1) to receive 450 mg/d (group 1, n = 100) or 900 mg/d (grou...
متن کاملCytomegalovirus Viremia in Lung Transplant Recipients Receiving
Background: Cytomegalovirus (CMV) disease is an important cause of organ transplant-related morbidity and mortality. During the last 5 years at our institution, prophylactic ganciclovir and hyperimmune globulin have been routinely administered to lung transplant recipients whenever the donor or the recipient was CMV antibody-positive. We sought to assess the efficacy of prophylaxis on viremia, ...
متن کاملThe CARI guidelines. CMV disease and kidney transplant: treatment of cytomegalovirus disease in renal transplant recipients.
We suggest ganciclovir by IV administration be the treatment of choice for moderate-severe Cytomegalovirus (CMV) disease and patients with gastrointestinal involvement where drug absorption may be impaired. Mild CMV disease in adults may be treated with either oral valganciclovir or IV ganciclovir (Level II evidence, single study). Drug dose should be reduced in patients with renal impairment. ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Open Forum Infectious Diseases
سال: 2016
ISSN: 2328-8957
DOI: 10.1093/ofid/ofw172.1840